Table 1 Basic characteristics of the included studies.

Study

Year

No. of patients(T/C)

Age (years)

(range, mean ±

SD)

Course of disease(range, mean ±

SD)

Sex

(Male/Female)

Therapeutic method(T/C)

Dosage

Duration

Outcome

Bao¹⁸

2020

60/60

T:64.7 ± 2.2

T:13.87 ± 1.52 months

not provide

A + B/B

A: 0.72 g, bid;

8 weeks

①②④⑤⑥

C:65.1 ± 2.4

C:14.25 ± 1.37 months

B: 10–20 mg qd.

Zhu¹⁹

2019

57/56

T:68.23 ± 4.08

not provide

T:28/29

A + B/B

A: 0.72 g, bid;

8 weeks

①②③④⑤⑥

C:67.47 ± 4.12

C:30/26

B: 10–20 mg qd.

He²⁰

2018

50/50

T:63.3 ± 3.6

T:2.3 ± 2.1 years

not provide

A + B/B

A: 0.72 g, bid;

8 weeks

①⑥

C:64.1 ± 2.9

C:2.0 ± 2.4 years

B: 5–20 mg qd.

Li²¹

2018

60/60

T:67.9 ± 4.7

not provide

T:32/28

A + B/B

A: 0.72 g, bid;

12 weeks

⑥

C:68.3 ± 4.6

C:33/27

B: 5–20 mg qd.

Ni²²

2017

49/49

T:67.85 ± 7.93

T:13.02 ± 2.89 years

T:28/21

A + B/B

A: 0.72 g, bid;

8 weeks

①②

C:66.14 ± 8.32

C:12.46 ± 3.08 years

C:26/23

B: 5–20 mg qd.

Lin²³

2016

30/30

T:67.6 ± 6.1

T:11.3 ± 7.3 months

T:14/16

A + B/B

A: 0.72 g, bid;

6 weeks

①②③⑥

C:68.75 ± 6.9

C:12.1 ± 8.1 months

C:15/15

B: 5–20 mg qd.

Wang²⁴

2016

43/43

T:66.45 ± 7.09

T:5.45 ± 1.28 years

T:16/27

A + B/B

A: 0.72 g, bid;

8 weeks

①②③⑥

C:65.3 ± 4.5

C:6.07 ± 1.36 years

C:16/18

B: 10–20 mg qd.

Zhang²⁵

2015

34/34

T:63.7 ± 3.5

T:2.8 ± 2.1 years

T:19/15

A + B/B

A: 0.72 g, bid;

8 weeks

①②③⑥

C:65.3 ± 4.5

C:1.5 ± 2.1 years

C:16/18

B: 5–20 mg qd.